Nevro Corp. (NVRO) News

Nevro Corp. (NVRO): $12.32

0.03 (+0.24%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

C

Filter NVRO News Items

NVRO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVRO News Highlights

  • For NVRO, its 30 day story count is now at 4.
  • Over the past 21 days, the trend for NVRO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • INGN are the most mentioned tickers in articles about NVRO.

Latest NVRO News From Around the Web

Below are the latest news stories about NEVRO CORP that investors may wish to consider to help them evaluate NVRO as an investment opportunity.

3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.

Yahoo | December 26, 2023

Activist investor takes stake in Nevro amid struggles to grow neuromodulation sales

Engaged Capital is opposed to Nevro going after acquisitions that may jeopardize its core business, Bloomberg reported Monday.

Yahoo | December 12, 2023

Inogen (INGN) Down 4.2% Since Last Earnings Report: Can It Rebound?

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 7, 2023

What's in Store for Cooper Companies (COO) in Q4 Earnings?

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

Yahoo | December 5, 2023

Nevro buys low back pain company Vyrsa for $40M

The company expects the acquisition to be revenue accretive starting in 2024.

Yahoo | December 4, 2023

Nevro (NVRO) Up 15.7% Since Last Earnings Report: Can It Continue?

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 1, 2023

Nevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment

Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.

Yahoo | December 1, 2023

Nevro Announces Acquisition of Vyrsa™ Technologies

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has acquired Vyrsa Technologies ("Vyrsa"), a privately held medical technology company focused on a minimally invasive treatment option for patients suffering from chronic sacroiliac joint ("SI Joint") pain.

Yahoo | November 30, 2023

Wall Street Analysts Predict a 36.66% Upside in Nevro (NVRO): Here's What You Should Know

The mean of analysts' price targets for Nevro (NVRO) points to a 36.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 23, 2023

Nevro's (NVRO) New Data Supports SCS Therapy for NSRBP Treatment

Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency.

Yahoo | November 21, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!